Business Context and Reporting Period
Company: Synthetic Blood International, Inc. (Note: Request metadata listed "Tenax Therapeutics," but the filing text identifies the registrant as Synthetic Blood International, Inc.)
Reporting Period: Quarterly period ended January 31, 2006 (Form 10-Q).
Business Stage: Development stage company focused on perfluorocarbon-based medical products, primarily "Oxycyte" (a synthetic blood substitute) and "Fluorovent" (an oxygen exchange fluid). The company has no commercial revenue and relies on financing to fund clinical trials.
Key Financial Metrics
| Metric | Three Months Ended Jan 31, 2006 | Nine Months Ended Jan 31, 2006 | Balance Sheet (Jan 31, 2006) |
|---|---|---|---|
| Revenue | $0 | $0 | N/A |
| Net Loss | $(860,537) | $(3,149,966) | Accumulated Deficit: $(26,772,697) |
| Total Expenses | $881,244 | $3,199,799 | N/A |
| Cash and Equivalents | N/A | N/A | $152,653 |
| Working Capital | N/A | N/A | $142,307 |
| Convertible Debentures (Net) | N/A | N/A | $178,621 |
| Cash Flow from Operations | N/A | $(1,834,618) | N/A |
Material Changes vs. Prior Period
- Net Loss: The nine-month net loss increased to $3.15 million from $1.96 million in the prior year period. This increase was primarily driven by a $1.24 million rise in interest expense due to the amortization of discounts on convertible debentures and accelerated conversions.
- Operating Expenses: Total expenses for the nine months increased by approximately $1.23 million. Research and Development (R&D) expenses rose to $957,897 (from $834,068) due to increased Phase II clinical trial costs. General and Administrative (G&A) expenses decreased to $1.00 million (from $1.14 million) due to reduced investor relations costs, partially offset by accelerated amortization of patent agreement costs.
- Liquidity: Cash and cash equivalents decreased from $588,763 at April 30, 2005, to $152,653 at January 31, 2006, reflecting a net cash outflow of $436,110 for the nine-month period.
Outlook, Risks, and Management Commentary
- Going Concern: The filing explicitly states that the company's continuation as a going concern is dependent on obtaining additional financing. Management believes current funds will only sustain operations until the first quarter of 2006. There is no assurance that new financing will be secured.
- Clinical Trials:
- Oxycyte: Phase II trials are ongoing. Enrollment in an orthopedic surgery trial was temporarily halted to refocus resources. A trial for sickle cell crisis is on clinical hold pending FDA protocol changes. A brain ischemia trial is expected to start in Q1 2006.
- Cost Estimates: Management estimates an additional $8 million is required to complete Phase II trials in 2006 and 2007.
- Accounting Changes: The company is required to adopt SFAS No. 123(R) effective May 1, 2006, which will require expensing stock-based compensation using the fair value method, expected to increase non-cash charges.
- Debt: The company issued $1.85 million in convertible debentures in July 2005. Significant interest expense is recognized due to the amortization of original issue discounts and beneficial conversion features.
Investor Verification Checklist
- Capital Runway: Verify if the company has secured the additional financing required to operate beyond the first quarter of 2006, as current cash ($152k) is insufficient for the estimated $8 million needed for Phase II trials.
- Debt Conversion: Review the terms of the $1.85 million convertible debentures, specifically the conversion price ($0.22) and the impact of further conversions on shareholder dilution.
- Clinical Holds: Monitor the status of the FDA clinical hold on the sickle cell crisis trial and the resolution of protocol changes.
- Stock-Based Compensation: Assess the potential impact of the upcoming adoption of SFAS 123(R) on future reported net losses.
- Related Party Transactions: Note payments made to a specialty contract manufacturer where an officer of the company is a minority shareholder and director.